Altimmune Initiates PERFORMA Phase 3 Trial Of Pemvidutide In Patients With MASH
ALT•Expected data readout
Altimmune said 52-week data readout from the PERFORMA Phase 3 trial is anticipated in 2029.
Phase 3 trial initiation
Altimmune Inc. said it has initiated the PERFORMA Phase 3 trial of pemvidutide in patients with MASH.
